Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
- None.
- None.
Insights
The Guardant Reveal blood test's ability to detect minimal residual disease (MRD) in early-stage colon cancer could significantly impact patient outcomes. MRD is a term referring to the small number of cancer cells that remain in the body after treatment and may lead to disease recurrence. The high specificity and predictive value of the test for recurrence, as indicated by the COSMOS study, suggests a potential reduction in unnecessary adjuvant therapies, which often come with significant side effects. This could lead to a more personalized treatment approach, sparing patients from the toxicities of chemotherapy when it's not needed.
Moreover, the capacity to predict disease recurrence without tissue specimens simplifies the process and could make post-operative monitoring more accessible. This non-invasive methodology aligns with current trends in precision medicine, aiming to tailor treatment strategies to individual patient profiles. The long-term implications for healthcare systems could include lower costs and improved allocation of resources if the test can reliably identify patients who would most benefit from additional therapy.
From a research perspective, the interim data from the COSMOS study not only validates the clinical utility of the Guardant Reveal test but also underscores the importance of continuous innovation in liquid biopsy technologies. The Guardant Infinity platform represents a significant advancement in the field, potentially setting a new standard for MRD detection. As Guardant Health continues to present data at scientific symposiums, the credibility and adoption of their technology in clinical settings could increase.
Furthermore, the company's diverse range of poster presentations at the ASCO GI Symposium, including those focusing on predictive markers for treatment resistance, emphasizes its commitment to expanding the applications of its technology. This could lead to broader market opportunities and partnerships within the oncology community. The ability to identify targetable mutations and resistance patterns is crucial for advancing personalized medicine and could lead to improved patient stratification in clinical trials and more effective treatment regimens.
Guardant Health's presentation of the COSMOS study results has strategic implications for its position in the precision oncology market. The early detection of MRD and the prediction of disease recurrence are areas of high unmet need and advancements in this space could translate into significant market growth. Guardant Health's stock (Nasdaq: GH) may respond positively to these interim results, reflecting investor confidence in the company's growth potential and its ability to capture a larger share of the oncology diagnostics market.
Investors will be closely monitoring the adoption rate of the Guardant Reveal test post-symposium and any strategic partnerships or collaborations that may arise from it. The test's performance and the robustness of the data presented could influence reimbursement decisions and guidelines, which are critical factors in market penetration. The long-term success of Guardant Health will depend on the sustained clinical validation of its products and the ability to navigate the regulatory landscape effectively.
COSMOS study shows Guardant Reveal™ blood test highly predictive for disease recurrence in patients with early-stage colon cancer without need for tissue specimen
Guardant Reveal analyzes comprehensive molecular signals in the blood to detect and quantify minimal residual disease (MRD). The COSMOS study evaluated the use of the newest version of the test, built on the Guardant Infinity™ smart liquid biopsy platform, to identify MRD and predict disease recurrence in 130 patients with early-stage (II and III) colon cancer. Interim data to be shared at ASCO GI suggest the test is both highly specific (low false positives) and predictive for recurrence, without dependence on a tissue sample.
“Studies have established the presence of residual disease after surgery is associated with a higher probability of recurrence in early-stage colon cancer,” said Craig Eagle, M.D., Guardant Health chief medical officer. “The interim COSMOS data are very promising and support the use of Guardant Reveal to predict disease recurrence and help inform adjuvant therapy decisions for patients with Stage II or III colon cancer.”
Guardant and its research partners will also present multiple posters at the symposium highlighting the application of Guardant technology in blood-based screening and in identifying potentially targetable mutations in GI cancers, including predictive markers for treatment resistance.
Guardant Health 2024 ASCO GI Poster Presentations
Guardant Reveal
- Multiomic Analysis for Minimal Residual Disease Detection: Addressing Challenges in Stage II-III Colon Cancer from COSMOS-CRC-01 (Abstract 180 | Poster Bd L8)
- Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer (ACT3) (Abstract 148 | Poster Bd J14)
- Phase II results of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) Phase II/III Study (Oral Abstract Session; Abstract 5)
Guardant360®
- The genomic landscape of advanced colorectal adenocarcinoma patients with PIK3CA mutations using comprehensive cell free tumor DNA next generation sequencing (Abstract 181 | Poster Bd L9)
- Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer (Abstract 170 | Poster Bd K18)
GuardantINFORM™
- Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC) (Abstract 158 | Poster Bd K6)
- Real-world testing and treatment patterns and outcomes following liquid biopsy in advanced cholangiocarcinoma (Abstract 455 | Poster Bd A20)
- Assessment of circulating tumor DNA (ctDNA) burden and association with outcomes in metastatic gastric cancer (mGC) patients using real-world data (RWD) (Abstract 276 | Poster Bd C14)
Shield™
- Enhanced blood-based colorectal cancer screening with improved performance in detection of early stage disease (Abstract 68 | Poster Bd E11)
- Circulating tumor DNA (ctDNA) positivity and its association with clinicopathological characteristics by novel blood-based test for colorectal cancer (CRC) screening from a multi-center large cohort: COSMOS-CRC-01 (Abstract 69 | Poster Bd E12)
- Prospective study of a multi-modal blood-based test for colorectal cancer screening (Abstract 70 | Poster Bd E13)
The full abstracts are available on the official ASCO 2024 GI Cancers Symposium website.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2022, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117367538/en/
Investor Contact:
investors@guardanthealth.com
Media Contact:
Michael Weist
press@guardanthealth.com
+1 650-647-3643
Source: Guardant Health, Inc.
FAQ
What study is being presented at the ASCO 2024 Gastrointestinal Cancers Symposium?
What is the purpose of the COSMOS study?
How does Guardant Reveal analyze molecular signals?
What is the significance of the interim data from the COSMOS study?
Where can the full abstracts of the presentations be found?
